GlassScriptPhysician profile
Ibrahim Mohammed
NPI 1215429675
$673.38
in general payments reported to CMS, 2019-2025
12 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.59 · 2021: $20.84 · 2022: $37.00 · 2023: $22.74 · 2024: $301 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $518.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $517.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $181.58 | 2019-2024 | Xarelto |
| Biotronik INC. | $162.16 | 2024-2025 | Acticor 7 Vr-T Dx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.57 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $60.34 | 2024-2025 | |
| Abiomed | $48.59 | 2025 | |
| Abbvie INC. | $39.81 | 2022-2023 | |
| Abbott Laboratories | $23.16 | 2025 | Cardiomems |
| Kestra Medical Technology Services, INC. | $22.59 | 2025 | Assure Wcd |
| Pfizer INC. | $20.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.93 | 2022 | |
| Edwards Lifesciences Corporation | $17.81 | 2024 | Sapien 3 Ultra Resilia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Mohammed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.